Scorpion Therapeutics to Present Preclinical Data for Potential Best-in-Class Mutant-Selective PI3Kα Inhibitor at San Antonio Breast Cancer Symposium
Scorpion Therapeutics, Inc. (Scorpion), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced that it will present preclinical data on STX-478, its potential best-in-class mutant-selective PI3K inhibitor, in a poster session at San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, taking place December 6 10, 2022.